Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Anti-Cancer MAbS Market Size from 2025 to 2034?
There has been substantial growth in the anti-cancer MAbS market in the recent past. The market is projected to surge from $65.35 billion in 2024 to $71.25 billion in 2025, registering a compound annual growth rate (CAGR) of 9.0%. Factors such as rising cancer occurrence rates, enhanced understanding of cancer biology, proliferation of personalized medicine tactics, increased funding in research and development, and heightened patient consciousness and demand are credited for the growth experienced during the historic period.
The narket size for anti-cancer MAbS is anticipated to witness notable expansion in the coming years, reaching $102.74 billion by 2029, with a compound annual growth rate (CAGR) of 9.6%. The projected growth during this period is fuelled by progress in immunotherapy, the increasing popularity of combination therapies, the emergence of next-gen mAbs, the global initiatives dealing with cancer burden, and the enlargement of patient access programs. The forecast period is characterized by trends such as breakthroughs in drug delivery technologies, the incorporation of artificial intelligence into drug discovery, collaborations and alliances within the pharma sector, biotechnological advancements, and car-t cell therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp
What are the Fundamental Drivers and Innovations Shaping the Anti-Cancer MAbS Market?
The global rise in cancer cases is predicted to stimulate the growth of the anticancer MABs market. Regarded as a chronic disease, cancer displays longevity in its duration. Specifically designed anticancer monoclonal antibodies (mAbs) work by adhering to distinct proteins found on cancer cells. They employ versions of the body’s immune system antibodies, which have been genetically engineered, to identify and eliminate cancer cells. Consequently, an elevated prevalence of cancer boosts the demand for anticancer MABs market. For example, PubMed, an American biomedical and life science journal, approximated in January 2022 that around 1.9 million new instances of cancer would be identified worldwide, encompassing 609,360 cancer-related fatalities in the United States. Thus, the increasing occurrence of cancer globally is fueling the expansion of the anticancer mAbs market.
How Is the Anti-Cancer MAbS Market Segmented?
The anti-cancer mabs market covered in this report is segmented –
1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types
2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications
3) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes
2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes
3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes
4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=9041&type=smp
Which Regions Are Driving the Next Phase of the Anti-Cancer MAbS Market Growth?
North America was the largest region in the anti-cancer MAbS market in 2024. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Key Trends Are Shaping the Future of the Anti-Cancer MAbS Market?
An emerging trend in the anticancer mAbs market centers on product innovations being launched by key players in the industry. By introducing novel, more efficient cancer treatments such as mAbs drugs, these companies are seeking to consolidate their market presence. For instance, May 2022 saw Switzerland’s pharmaceutical giant, Roche Holding AG, launch PHESGO, a unique treatment for HER2-positive early breast cancer. PHESGO, which is a combination of the monoclonal antibodies (mAbs) pertuzumab and trastuzumab and the enzyme hyaluronidase, represents an innovation in treatment adminstration. It’s a subcutaneous injection (beneath the skin) which uses hyaluronidase to enhance the absorption of the mAbs, thereby allowing for the treatment to be administered subcutaneously instead of intravenously.
View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report
How Is the Anti-Cancer MAbS Market Defined and What Are Its Core Parameters?
Anticancer monoclonal antibodies (mAbs) are the antibodies used for monoclonal antibody therapy to target and destroy cancer cells. These mAbs are intended to bind to specific proteins or chemicals located on the surface of cancer cells, preventing cancer growth, and spread.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9041
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
